<DOC>
	<DOCNO>NCT00325104</DOCNO>
	<brief_summary>This study evaluate benefit side effect new medication call Cinacalcet treat patient primary hyperparathyroidism associate multiple endocrine neoplasia type 1 ( MEN1 ) type 2A ( MEN2A ) . Patients primary hyperparathyroidism elevate level blood calcium cause much parathyroid hormone release one parathyroid tumor . The parathyroid small gland locate neck . Most case primary hyperparathyroidism due single overactive parathyroid gland , MEN1 MEN2A , several gland overgrown overactive . Cinacalcet decrease secretion parathyroid hormone . Patients 18 year age old primary hyperparathyroidism MEN1 MEN2A candidate parathyroid surgery may eligible study . Participants admit Clinical Center 1 week blood urine test image study , initiation Cinacalcet treatment . They take drug mouth daily blood test dosage require achieve normal blood calcium level determine . Patients return hospital 2 week later 1 week evaluate response drug make necessary adjustment . Treatment may continue long 1 year 1-week admission every 3 month monitor benefit side effect Cinacalcet . Evaluations may include follow : - Blood urine analysis . - Measurement gastric acid secretion . For test , soft plastic tube insert nose mouth swallow gently remove hour later . - Injections secretin , calcium arginine vein collection blood sample measure respond increase level gastrin , calcitonin insulin , respectively . These test use diagnose monitor hormone secretion endocrine tumor use study assess response Cinacalcet treatment . - Radioisotope test evaluate tumor endocrine organ . A radioactive substance inject vein take endocrine tissue concentrate radioactivity measure . - Imaging test , MRI CT , detect follow grow tumor pituitary , neck , abdomen . CT special type x-ray machine visualizes tissue , thyroid parathyroid tumor . MRI use magnetic field radio wave obtain picture different tissue head , neck abdomen . - DEXA scan ass bone density . This test use standard low-intensity x-ray .</brief_summary>
	<brief_title>Cinacalcet Treat Familial Primary Hyperparathyroidism</brief_title>
	<detailed_description>This study evaluate safety efficacy short- long-term Cinacalcet treatment hypercalcemia familial primary hyperparathyroidism . The study population include patient primary hyperparathyroidism cause multiple endocrine neoplasia type 1 type 2A . This prospective unblinded pilot study , patient serve his/her control . It include 6 one-week-long admission , 1 year period . Main measurement test hyperparathyroidism parathyroid hormone serum calcium well test nonparathyroid tumor . The latter test may include hormone release tumor image tumor .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>INCLUSION CRITERIA : Criteria inclusion 1 . Patients primary hyperparathyroidism associate MEN1 2A syndrome indication current surgical intervention . 2 . For initial pilot study , 1520 patient MEN1 syndrome biochemical evidence hyperparathyroidism include . 3 . For initial pilot study , 510 patient MEN2A syndrome biochemical evidence hyperparathyroidism include . Each MEN2A case must residual MTC tumor . 4 . In case ZES , good acidity control proton pump inhibitor ( PPI ) , document basal acid output ( BAO ) less 10 mEq/h . 5 . Willingness legal ability give inform consent . 6 . MEN1 , like MEN2A normal gender ethnic distribution . These maintain , within limit small number subject study . EXCLUSION CRITERIA : Criteria exclusion removal 1 . Age le 18 year 2 . Pregnancy 3 . Creatinine great 1.4 4 . SGOT SGPT great twice normal 5 . Indications current surgery : 1 . Hyperparathyroidism Albuminadjusted serum calcium level high 3.0 mmol/L ( 12.0 mg/dL ) Kidney stone Significant PTHinduced bone disease Age 50 consider absolute indication parathyroid surgery herein 2 . Enteropancreatic neuroendocrine neoplasia Single lesion meeting criterion surgery Need debulking surgery obstructive complication Acute abdominal complication kind Inability control PPI case ZES 6 . Chemotherapy within last 6 month 7 . Lactating female 8 . Patients contraindication MRI study , include pacemaker , vascular clip , implant , foreign body etc. , per NIHMRI Safety Guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 31, 2007</verification_date>
	<keyword>Multiple Endocrine Neoplasia</keyword>
	<keyword>Gastrinoma</keyword>
	<keyword>Prolacinoma</keyword>
	<keyword>Medullary Thyroid Cancer</keyword>
	<keyword>Insulinoma</keyword>
	<keyword>MEN1</keyword>
	<keyword>MEN2A</keyword>
	<keyword>Familial Primary Hyperparathytoidism</keyword>
</DOC>